{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:15:13Z","timestamp":1780143313572,"version":"3.54.0"},"reference-count":14,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N00633X\/1"],"award-info":[{"award-number":["MR\/N00633X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To evaluate the association between metformin use and anemia risk in type 2 diabetes, and the time-course for this, in a randomized controlled trial (RCT) and real-world population data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Anemia was defined as a hemoglobin measure of &amp;lt;11 g\/dL. In the RCTs A Diabetes Outcome Progression Trial (ADOPT; n = 3,967) and UK Prospective Diabetes Study (UKPDS; n = 1,473), logistic regression was used to model anemia risk and nonlinear mixed models for change in hematological parameters. In the observational Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) population (n = 3,485), discrete-time failure analysis was used to model the effect of cumulative metformin exposure on anemia risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>In ADOPT, compared with sulfonylureas, the odds ratio (OR) (95% CI) for anemia was 1.93 (1.10, 3.38) for metformin and 4.18 (2.50, 7.00) for thiazolidinediones. In UKPDS, compared with diet, the OR (95% CI) was 3.40 (1.98, 5.83) for metformin, 0.96 (0.57, 1.62) for sulfonylureas, and 1.08 (0.62, 1.87) for insulin. In ADOPT, hemoglobin and hematocrit dropped after metformin initiation by 6 months, with no further decrease after 3 years. In UKPDS, hemoglobin fell by 3 years in the metformin group compared with other treatments. At years 6 and 9, hemoglobin was reduced in all treatment groups, with no greater difference seen in the metformin group. In GoDARTS, each 1 g\/day of metformin use was associated with a 2% higher annual risk of anemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Metformin use is associated with early risk of anemia in individuals with type 2 diabetes, a finding consistent across two RCTs and replicated in one real-world study. The mechanism for this early fall in hemoglobin is uncertain, but given the time course, is unlikely to be due to vitamin B12 deficiency alone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc20-1104","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T01:55:43Z","timestamp":1597456543000},"page":"2493-2499","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":60,"title":["Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study"],"prefix":"10.2337","volume":"43","author":[{"given":"Louise A.","family":"Donnelly","sequence":"first","affiliation":[{"name":"Population Health & Genomics, School of Medicine, University of Dundee, Dundee, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Dennis","sequence":"additional","affiliation":[{"name":"Institute of Biomedical & Clinical Science, University of Exeter Medical School, Royal Devon & Exeter Hospital, Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-8550","authenticated-orcid":false,"given":"Ruth L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medicine Sciences, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-473X","authenticated-orcid":false,"given":"Andrew T.","family":"Hattersley","sequence":"additional","affiliation":[{"name":"Institute of Biomedical & Clinical Science, University of Exeter Medical School, Royal Devon & Exeter Hospital, Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-874X","authenticated-orcid":false,"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medicine Sciences, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-8585","authenticated-orcid":false,"given":"Ewan R.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Population Health & Genomics, School of Medicine, University of Dundee, Dundee, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"2022031223550596800_B1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/diacare.26.4.1164","article-title":"Unrecognized anemia in patients with diabetes: a cross-sectional survey","volume":"26","author":"Thomas","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031223550596800_B2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/1753-0407.12900","article-title":"Associations between metformin use and vitamin B12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis","volume":"11","author":"Yang","year":"2019","journal-title":"J Diabetes"},{"key":"2022031223550596800_B3","first-page":"386","article-title":"Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin","volume":"71","author":"de Groot-Kamphuis","year":"2013","journal-title":"Neth J Med"},{"key":"2022031223550596800_B4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1185\/03007995.2010.542081","article-title":"Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA)","volume":"27","author":"Karamanos","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2022031223550596800_B5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2337\/dc11-1582","article-title":"Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999-2006","volume":"35","author":"Reinstatler","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031223550596800_B6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/pdi.1392","article-title":"Metformin and anaemia: myth or reality","volume":"26","author":"Adetunji","year":"2009","journal-title":"Pract Diabetes Int"},{"key":"2022031223550596800_B7","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study","volume":"101","author":"Aroda","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223550596800_B8","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031223550596800_B9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031223550596800_B10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031223550596800_B11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ije\/dyx140","article-title":"Cohort profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS)","volume":"47","author":"H\u00e9bert","year":"2018","journal-title":"Int J Epidemiol"},{"key":"2022031223550596800_B12","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s00125-012-2668-0","article-title":"Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs","volume":"55","author":"Colhoun","year":"2012","journal-title":"Diabetologia"},{"key":"2022031223550596800_B13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.clpt.6100146","article-title":"Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus","volume":"82","author":"Berria","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2022031223550596800_B14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc20-1104","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/10\/2493\/630013\/dc201104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/10\/2493\/630013\/dc201104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:52:54Z","timestamp":1647143574000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/10\/2493\/35897\/Risk-of-Anemia-With-Metformin-Use-in-Type-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,8,14]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-1104","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]}}}